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Abstract
Neurofibromatosis 1 (NF1) is an autosomal-dominant multisystemic  
neurocutaneous disorder primarily affecting the skin, bone and the nervous 
system. It has been long appreciated that NF1 is often associated with endocrine 
disorders. In this chapter, we will discuss the endocrine disorders associated 
with NF1. The most common endocrinological disorders in NF1 are short stature 
with or without growth hormone deficiency, central precocious puberty, growth 
hormone excess. Less common endocrine-related conditions in NF1 include 
gynecomastia, diencephalic syndrome and the presence of endocrine tumors like 
pheochromocytoma.
Keywords: NF1, endocrine conditions, short stature, GHD, growth hormone excess, 
central precocious puberty, endocrine tumors
1. Introduction
Neurofibromatosis 1 (NF1) is an autosomal-dominant multisystemic neurocuta-
neous disorder primarily affecting the skin, bone and the nervous system. The inci-
dence has been described to be around 1 in 2500–3500 live births, and the estimated 
prevalence is 1 in 4000–5000. The penetrance is complete, but the severity of the 
clinical manifestations is variable and unpredictable, even within affected families 
[1]. Approximately one-half of the cases are familial and the remainder arise from a 
de novo NF1 mutation. The diagnosis of NF1 relies primarily on the clinical grounds, 
which is based on the National Institutes of Health (NIH) diagnostic criteria [2], as 
described in the other chapter.
In this chapter, we will discuss endocrine disorders associated with NF1. 
The association of NF1 with endocrinopathies has been reported since 1920 
[3]. The data on the incidence and prevalence of endocrine disorders in NF1 are 
scarce [4]. The most common endocrine disorders in NF1 are short stature with 
or without growth hormone deficiency (GHD), central precocious puberty, 
growth hormone excess (GHE). Less common endocrine-related conditions in 
NF1 include gynecomastia, diencephalic syndrome and the presence of endo-
crine tumors like pheochromocytoma. The most endocrine disorders in NF1 are 
thought to be related to central nervous system tumors compromising the hypo-
thalamic and pituitary function [1]. In a recent retrospective study, endocrine 





The protein product of the NF1 gene is a large cytoplasmic protein, neurofibro-
min. The neurofibromin coding sequence comprises a 300-amino acid sequence, 
with the GTPase-activating protein domain. Loss of neurofibromin function results 
in hyperactivation of the proto-oncogene RAS, as well as enhanced activity of RAS 
downstream effectors. In animal studies with a mouse model, loss of neurofibromin 
alone is insufficient to cause nervous system tumor formation and that additional 
genetic or environmental changes are probably necessary for tumor formation [5].
Neurofibromin also regulates intracellular cAMP generation in the brain. Cyclic 
AMP and the transcription factor called cAMP response element-binding protein 
(CREB) represent key regulators of hypothalamic-pituitary axis development. In 
animal models, brain-specific loss of CREB is known to cause hypopituitarism and 
poor growth [5, 6]. During embryonic differentiation, neurofibromin regulates the 
proliferation and maturation of both glial and neuronal progenitor cells [7]. The 
animal studies with a mouse model (Nf1BLBPCKO mice) with NF1 gene inactiva-
tion in neuroglial progenitor cells showed significantly reduced body weight and a 
small anterior pituitary gland with normal posterior pituitary. The anterior pitu-
itary hypoplasia reflects a loss of neurofibromin expression in the hypothalamus, 
leading to reduced growth hormone-releasing hormone (GHRH), growth hormone 
(GH) and insulin-like growth factor-1 (IGF1) production. GHRH gene expression 
analysis by immunohistochemistry in hypothalamic-pituitary tissue from these 
mice has shown a significant reduction in GHRH staining within the median emi-
nence. About 40–60% reduction in the GHRH mRNA was evident in the hypotha-
lamic cells of Nf1BLBPCKO mice, compared with wild-type controls.
3. Endocrine disorders in NF1
3.1 Short stature
Short stature is a well-recognized clinical feature of NF1. The risk factors for 
short statue in NF1 include suprasellar lesion, surgery or radiation for such lesions 
causing GHD and scoliosis or other skeletal abnormalities. Short stature has been 
reported in 13–33% of children with NF1 [8, 9]. After exclusion of risk factors, the 
short stature has been reported in 8% of children with NF1 [10]. Short stature in 
NF1 has been associated both with and without GHD.
The population with NF1 as a whole is significantly shorter than the general 
population and specific growth charts are available for children with NF1. Clementi 
et al. analyzed the growth profile of 528 children with NF1 based on the data 
collected through a population-based registry from three contiguous regions of 
North-East Italy, and created growth charts of height, weight and head circumfer-
ence (HC) for children with NF1 [11]. There was no difference in height between 
children with NF1 and normal children up to 7 years in girls and 12 years in boys. 
Beyond that age, the 50th centile of children with NF1 overlapped with the 25th 
centile of normal children and the 3rd centile of children with NF1 was significantly 
lower than the normal children. The height growth velocity was normal for both 
sexes in children with NF1 during childhood, but pubertal spurt was reduced in 
NF1 boys. Children with NF1 and normal children showed a similar median weight 
during the whole growth period. The 3rd centile for weight was consistently lower 
in children with NF1 during adolescence, and the 97th centile was higher during 
adulthood. The HC was larger in children with NF1 during the whole childhood and 
adulthood.
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These growth charts can be used in neurofibromatosis clinics for the identifica-
tion of secondary growth disorders, for growth prognosis and the evaluation of the 
effects of various treatments in children with NF1 [11].
3.2 Growth hormone deficiency (GHD)
The GHD is more common in children with NF1 compared to the general popu-
lation. Cnossen et al. found a prevalence of 2.5% among patients with NF-1, which 
is higher than the 0.03% observed in the general pediatric population [12]. The 
cause of GH deficiency in NF1 is not clear, but it is much more common in the pres-
ence of an intracranial tumor and in some cases, it is clearly related to the treatment 
of these tumors with surgery and radiotherapy [13, 14]. GHD is also seen in children 
with NF-1 without suprasellar abnormalities, which suggests an association with 
NF-1 independent of organic pituitary damage [9].
As children with NF1 have a greatly increased risk of malignancy, there has 
been concern about the safety of GH treatment in children with NF1. Howell et 
al. reviewed the safety and efficacy of growth hormone therapy in a cohort of 102 
children with both NF and biochemical evidence of GHD who had received GH 
replacement therapy at a mean dose of 0.18 mg/kg/week. During the 1st year, the 
median height velocity increased significantly from 4.2 cm/year before treatment 
to 7.1 cm/year, and the median height standard deviation score increased from −2.4 
to −1.9. Children with NF1 and GHD respond favorably to treatment with GH, but 
not as good as that seen in patients with idiopathic GHD. Most of the adverse events 
reported in this cohort during GH therapy were either relatively minor or unlikely to 
be directly attributable to GH therapy. Five GH-treated patients had either a recur-
rence of an intracranial tumor or a second intracranial tumor. This incidence of 
tumor occurrence was comparable to that previously reported in similar NF1 patients 
not treated with GH. GH therapy did not influence the progression of any of the fea-
tures of NF1, including intracranial tumors, and was not associated with an excess of 
other adverse events. Though controversial, GH treatment in NF1 patient is beneficial 
in terms of growth rate [15]. There is a need for prospective and randomized studies 
to test the efficacy, risk and safety of GH therapy in this population.
3.3 Central precocious puberty (CPP)
Central precocious puberty is the most common endocrine disorder in children 
with NF1. The prevalence of this disorder in patients with NF1 is 3%, which is 
markedly higher than the prevalence of about 0.6% reported in the general pediat-
ric population [1]. Central precocious puberty is reported more often in girls than in 
boys, while precocious puberty in NF1 is observed more in boys [12, 16].
Precocious puberty in NF1 almost occurred invariably in association with optic 
pathway tumors, especially when optic chiasm is involved [16]. This supports the 
theory that lesions located near the hypothalamus interfere with the tonic Central 
nervous system inhibitions of the hypothalamic-pituitary-gonadal axis, resulting 
in the premature onset of puberty [17]. However precocious puberty in NF1 has 
also been reported in the absence of optic glioma [12]. Saxena reported two cases of 
precocious puberty in patients with NF1 without tumors of the optic chiasm, but no 
imaging was available at that time, which leaves open the possibility of undetected 
tumors [3]. In the study reported by Cnossen et al., CPP was diagnosed in 3 of 122 
children but only 1 child had an OPG at MRI showing that optic chiasm glioma is 
not a prerequisite for CPP [12]. This could possibly be due to some cerebral abnor-
mality undetected by neuroimaging or due to abnormalities at the cellular level 
involving neurofibromin. Other tumors like hypothalamic hamartoma that causes 
Neurofibromatosis
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precocious puberty in the general population have also been reported to cause 
precocious puberty in patients with NF1 [18].
Treatment of NF1 children with CPP is similar to those approved for children 
with idiopathic or organic CPP not related to NF1. Pubertal progression in CPP is 
treated by administration of a gonadotropin-releasing hormone (GnRH) agonist. 
These agents act by causing continuous stimulation of the pituitary gonadotrophs, 
instead of physiologic pulsatile stimulation from hypothalamic GnRH and this 
continuous stimulation leads to desensitization of the gonadotroph cells and sup-
pression of gonadotropins, resulting in decreased sex steroid production. These 
treatments are mostly effective in children with younger age at the onset of puberty 
or with a progressive decline in predicted adult height.
In contrast to precocious pubertal development, a very high incidence of delayed 
menarche among NF1 girls has been reported [19].
3.4 GH excess
GH excess is generally a rare disease in children and adults but affects patients 
with NF1 at higher rates. It is mostly observed in the presence of OPG located inside 
the hypothalamic area or close to it. The prevalence of GH excess in patients with 
NF1 is unknown. Cambiaso et al. noted that 10% of the population with NF1 had 
abnormalities in the GH axis consistent with GH excess. All the affected patients 
studied by Cambiaso et al. had a tumor involving the optic chiasm, without pitu-
itary involvement [20].
The mechanism underlying GH excess in NF1 is unknown. It has been postulated 
that the presence of OPT, particularly those involving the hypothalamic and sellar 
regions, inhibits somatostatin tone allowing for the unregulated release of GH. Some 
authors proposed the presence of overactive GH-releasing hormone in OPTs, although 
immunostaining for GHRH and GH were negative in some reported cases [21].
The diagnosis of GH excess in NF1 should be suspected in children with accel-
erated linear growth and clinical features of gigantism such as enlargement of 
the hands and feet, soft tissue thickening, coarse facial features, prognathism or 
worsening of clinical features such as neurofibromas, pain or endocrinopathies. 
Screening for GH excess in NF1 should be based on the existing guidelines for the 
diagnosis of gigantism and acromegaly. Initial screening includes the measurement 
of serum IGF-1 and GH levels that can be paired in a random sample. In patients 
with suspected GH excess with normal IGF1 and GH levels, a serial overnight GH 
sampling may be performed in specialized centers. GH excess is confirmed with 
elevated IGF-1 and lack of GH suppression to levels <1 ng/mL after the oral glucose 
tolerance test. Once confirmed, brain imaging is recommended to evaluate for OPT 
and to assess for lesions in the pituitary and hypothalamus [21].
Growth hormone excess in children with NF1 has been reported to be a transient 
phenomenon in some children and thus may not need treatment [22, 23]. In chil-
dren requiring treatment, somatostatin analogs and GH receptor antagonist have 
been used to reduce tumor growth and the long-term systemic effects related to 
uncontrolled GH excess. The outcome of the medical treatment has been reported 
only in a few cases [24] and there are limited data on the longitudinal course of 
patients treated with somatostatin analogs or GHR antagonists.
3.5 Diencephalic syndrome
Diencephalic syndrome (DS) is a rare endocrine disorder reported in children 
with NF1 and OPG. It is a clinical condition present in early infancy and is charac-
terized by failure to thrive despite adequate or slightly decreased food intake, severe 
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emaciation and hyper-alertness, associated with supratentorial midline space-
occupying lesions involving the hypothalamus.
DS is commonly reported within the first 2 years of life. But the median age of 
children diagnosed with DS associated with NF1 is slightly advanced, with only one 
case reported at age less than 12 months [25]. DS in an infant or a child with NF1 
usually indicates the presence of an undiagnosed OPG. Less often, it may become 
evident later with the progression of an already known OPG due to the enlargement 
of the tumor, which causes compression of the hypothalamus.
3.6 Gynecomastia
Gynecomastia is the growth of glandular breast tissue in males. Gynecomastia 
seen during puberty is physiologic, but gynecomastia with prepubertal-onset is 
very uncommon and suggests a different etiology such as gonadal steroid-secreting 
tumors, congenital adrenal hyperplasia, aromatase excess [26]. An increased fre-
quency of unilateral and bilateral prepubertal gynecomastia has been described in 
NF1 patients [27]. Endocrine workup was found normal in all the described cases, 
ruling out other etiologies of prepubertal gynecomastia. The exact etiology and 
pathogenesis of gynecomastia in NF1 are not clearly understood. It is thought to be 
due to pseudoangiomatous stromal hyperplasia of breast tissue secondary to a muta-
tion in neurofibromin [28]. Distinct histopathologic features seem to be associated 
with gynecomastia related to NF1. Standard pubertal gynecomastia is characterized 
by hypocellular fibrous stroma, with proliferative multilayered ductal epithelium, 
while NF-1-related gynecomastia is characterized by hypercellular fibrous stroma and 
a single layer of ductal epithelium [27]. A few cases of neurofibroma, hamartoma, 
lipomatous hyperplasia and pseudoangiomatous hyperplasia of the breast, mimicking 
gynecomastia (usually unilateral), have also been described in children with prepu-
bertal NF1 [29–31]. Surgery is indicated in cases of progressive breast enlargement.
4. Endocrine tumors in NF1
Patients with NF1 are at an approximately 2–4-fold higher risk of developing 
tumors than the general population. The gastrointestinal tract may be involved in 
NF-1 and includes gastrointestinal stromal tumors (GIST), carcinoids, pheochro-
mocytomas, paragangliomas and pancreatic neuroendocrine tumors. Gastrinomas, 
insulinomas and nonfunctioning pancreatic endocrine tumors have also been 
reported in patients with NF-1.
4.1 Pheochromocytoma
The incidence of pheochromocytoma among patients with NF1 is estimated 
to be 0.1–5.7% [32]. It is usually seen in adult patients with NF1. NF-1-associated 
pheochromocytomas are predominantly epinephrine-producing, and thus, patients 
present with paroxysmal symptoms. Approximately 60% of patients with pheo-
chromocytoma in the setting of NF-1 have sustained hypertension. Metabolites of 
epinephrine, such as metanephrines, can be measured in plasma by high-perfor-
mance liquid chromatography with electrochemical detection. Biochemical screen-
ing via serum fractionated metanephrines is recommended in patients with NF1 
in case of development of hypertension or other suggestive symptoms to exclude 
or confirm pheochromocytoma. If biochemical testing is positive, other imaging 
modalities such as CT, MRI and functional imaging with I123 metaiodobenzylgua-
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4.2 Optic pathway gliomas
The Optic Pathyway Gliomas occurs in 15-20% of children with NF1. These can  
involve the hypothalamus and lead to endocrine disorders [33]. A retrospective 
study by Sani et al. (n = 40) reported endocrinopathies in 55% of children with 
NF1 and OPG by the mean age of 7.4 years. This study reported GHD in 36%, CPP 
in 33% and GH excess in 5%. This study also reported that GHD was transient in 
patients who were retested. A recent multicenter retrospective study in children 
with NF1 and OPG (n = 116) showed 27% of children had endocrine dysfunction by 
age 7.8 years including CPP (72%) and GHD (10%), GHE (6%) and DS (12.5%) [4].
There are no specific recommendations for surveillance of patients with NF-1 
for endocrine tumors. However, due to the association of NF-1 with endocrine 
tumors, physicians should have a high index of suspicion in patients with symptoms 
suggestive of a neuroendocrine tumor and appropriate screening tests should be 
performed.
5. Conclusion
Children with NF1 are at risk for developing endocrinopathies such as CPP, 
GHD, GHE and DS. A close follow-up is crucial in NF1 patients especially in 
children with OPG, for early identification of endocrinopathies.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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